导师风采
张力
个人信息
Personal Information
- 性别：女
- 导师类型：博导
- 职称：主任医师
- 该职称任职时间：1996-08-20
联系方式
Contact Information
- 所属院系：北京协和医院
- 所属专业：
- 邮箱 : pumchzhangli@163.com
- 工作电话 : 13911339836
个人简介
Personal Profile
张力， 女，1962.10.26出生，1996年毕业于中国医学科学院北京协和医科大学，获硕士学位，博士研究生导师。2012年获得浙江省科学技术奖一等奖（排名第5）；2015年国家科学技术进步奖一等奖（排名第5）；2017年荣获中华医学会呼吸病分会“杰出呼吸学术贡献奖”。2019年“独墅湖杯”医药创新“最具影响力药物临床研究领军人物奖”，2020.1.22获得天津市科学技术进步奖一等奖，2020.7.25获得中国抗癌协会科技奖二等奖，多次获得院医疗成果奖。自1993年以来，师从于李龙芸教授，一直从事呼吸系统疾病，尤其是肺癌的临床科研和教学工作，积累了丰富的临床经验，受到很多病患的好评，拥有较多从众的病人群体，深得他们的信赖，成为该学科的青年骨干。注重科学研究， 先后得到过多项国家和部级科研课题（九五、十五、十一五、863和卫生部基金）的资助。承接完成或独立完成了30余项国际、国内Ⅰ、Ⅱ、Ⅲ期及注册的临床新药的研发。掌握药物治疗的前沿最新动态。发表研究论文著作60余篇。现为博士生导师，承担清华大学北京协和医科大学8年制学生、住院医师、进修医师、全科医师的教学培训工作，目前的社会兼职有：中华医学会肺癌学组成员、中国交叉科学学会委员国际呼吸杂志第六届编辑委员会委员和中国肺癌联盟肺癌联盟成员，《Interdisciplinary Science-Computational Life Sciences 》副主编。
团队简介
Team Profile
张力， 女，1962.10.26出生，1996年毕业于中国医学科学院北京协和医科大学，获硕士学位，博士研究生导师。2012年获得浙江省科学技术奖一等奖（排名第5）；2015年国家科学技术进步奖一等奖（排名第5）；2017年荣获中华医学会呼吸病分会“杰出呼吸学术贡献奖”。2019年“独墅湖杯”医药创新“最具影响力药物临床研究领军人物奖”，2020.1.22获得天津市科学技术进步奖一等奖，2020.7.25获得中国抗癌协会科技奖二等奖，多次获得院医疗成果奖。自1993年以来，师从于李龙芸教授，一直从事呼吸系统疾病，尤其是肺癌的临床科研和教学工作，积累了丰富的临床经验，受到很多病患的好评，拥有较多从众的病人群体，深得他们的信赖，成为该学科的青年骨干。注重科学研究， 先后得到过多项国家和部级科研课题（九五、十五、十一五、863和卫生部基金）的资助。承接完成或独立完成了30余项国际、国内Ⅰ、Ⅱ、Ⅲ期及注册的临床新药的研发。掌握药物治疗的前沿最新动态。发表研究论文著作60余篇。现为博士生导师，承担清华大学北京协和医科大学8年制学生、住院医师、进修医师、全科医师的教学培训工作，目前的社会兼职有：中华医学会肺癌学组成员、中国交叉科学学会委员国际呼吸杂志第六届编辑委员会委员和中国肺癌联盟肺癌联盟成员，《Interdisciplinary Science-Computational Life Sciences 》副主编。
- 研究方向Research Directions
胸部恶性肿瘤
- 在校研究生Current Graduate Students
硕士研究生 0 名，博士研究生 2 名
- 科研项目Research Projects
| # | 项目名称 | 起止日期 | 金额 | 项目类型 | 本人角色 |
|---|---|---|---|---|---|
| 1 | 卡瑞利珠单抗联合化疗（伊立替康联合铂类）序 贯卡瑞利珠单抗联合阿 帕替尼一线治疗晚期小细 胞肺癌的单臂、开放、前瞻性、单中心临床研 究 | 2020-07-01 —— | 15.0 | ||
| 2 | 一项前瞻、开放、单臂II期临床研究评估替雷利珠单抗联合安罗替尼治疗伴EGFR敏感突变且既往EGFRTKI治疗失败的非鳞非小细胞肺癌患者的疗效及安全性 | 2020-12-22 —— 2022-12-22 | 主持的企业/行业委托重大项目 | 主持人 | |
| 3 | 卡瑞利珠单抗联合化疗（伊立替康联合铂类）序贯卡瑞利珠单抗联合阿帕替尼一线治疗晚期小细胞肺癌的单臂、开放、前瞻性、单中心临床研究 | 2020-01-01 —— 2023-07-01 | 主持的企业/行业委托重大项目 | 主持人 | |
| 4 | 盐酸安罗替尼联合帕博利珠单抗一线治疗晚期非小细胞肺癌的探索性临床研究 | 2019-07-23 —— 2021-04-15 | 主持的企业/行业委托重大项目 | 主持人 | |
| 5 | 高龄肺栓塞患者新型口服抗凝药的疗效及安全性研究 | 2019-05-01 —— 2020-05-15 | 主持的企业/行业委托重大项目 | 主持人 | |
| 6 | 阿替利珠单抗联合化疗一线治疗广泛期小细胞肺癌安全性和有效性的真实世界研究 | 2020-06-01 —— 2021-12-01 | 主持的企业/行业委托重大项目 | 主持人 | |
| 7 | Durvalumab在中国局部晚期不可切除非小细胞肺癌（III期） 患者的数据总结及中国人群中安全性数据管理的真实世界研究 | 2020-07-01 —— 2022-07-01 | 主持的企业/行业委托重大项目 | 主持人 |
- 发表论文Papers
| # | 论文题目 | 期刊名称 | 发表年份 | 论文署名 |
|---|---|---|---|---|
| 1 | Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer | Thoracic Cancer | 2022-06-19 | 张力 |
| 2 | Treatment of steroid-resistant checkpoint inhibitor pnuemonitis with prifenidone:A case report | Thoracic Cancer | 2022-06-19 | 张力 |
| 3 | Non-small-cell lung cancer with ERBB2 mutation in non-tyrosine kinase domain benefits from pyrotinib: A case report | Thoracic Cancer | 2022-06-19 | 张力 |
| 4 | Clinical recommendations for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer | Thoracic Cancer | 2022-06-19 | 张力 |
| 5 | Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non-small cells lung cancer | Frontiers in immunology | 2022-06-17 | 张力 |
| 6 | Clinical characteristics and prognositc model for extensive-stage small cell lung cancer :A retrospective study over an 8-year period | Thoracic Cancer | 2022-06-19 | 张力 |
| 7 | Routine-Dose and High-Dose Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II, INCREASE Trial | CLINICAL CANCER RESEARCH | 2020-02-14 | 第一作者 |
| 8 | Randomized clinical trial of pembrolizumab vs chemotherapy | INTERNATIONAL JOURNAL OF CANCER | 2020-10-22 | 第一作者 |
| 9 | Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib | Therapeutic Advances in Medical Oncology | 2023-11-07 | 第一作者 |
| 10 | pembrolizumab in a patient with squamous cell lung cancer | Journal of Thoracic Oncology | 2019-02-13 | 通讯作者 |
| 11 | Real-world evidenceand clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors | Scientific Reports | 2019-03-01 | 通讯作者 |
| 12 | Management of anlotinib-related adverse events in patients with advanced non-small cell lung cancer: Experiences in ALTER-0303 | THORACIC CANCER | 2019-03-01 | 通讯作者 |
| 13 | Curative effect assessment of immunotherapy for non-small cell lung cancer: The "blind area" of Immune Response Evaluation Criteria in Solid Tumors (iRECIST) | Thoracic Cancer | 2019-04-01 | 通讯作者 |
| 14 | Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors | Thoracic Cancer | 2019-05-01 | 通讯作者 |
| 15 | Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer | OncoTargets and Therapy | 2019-05-01 | 通讯作者 |
| 16 | Correlation Between PD-L1 Expression and Clinicopathologic Features in 404 Patients with Lung Adenocarcinoma | Interdisciplinary Sciences-Computational Life Sciences | 2019-05-11 | 通讯作者 |
| 17 | Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease | ONCOTARGETS AND THERAPY | 2019-07-01 | 通讯作者 |
| 18 | Tracheoesophageal Fistula Caused by Successful Response to Pembrolizumab in a Patient With Squamous Cell Lung Cancer | JOURNAL OF THORACIC ONCOLOGY | 2019-07-01 | 通讯作者 |
| 19 | Eltrombopag treatment for severe refractory thrombocytopenia caused by pembrolizumab | EUROPEAN JOURNAL OF CANCER | 2019-08-12 | 通讯作者 |
| 20 | Management of Immune Checkpoint Inhibitor-Related Rheumatic Adverse Events | Thoracic Cancer | 2019-11-24 | 通讯作者 |
| 21 | Clinical diagnosis and treatment of immune checkpoint inhibitor-associated pneumonitis | THORACIC CANCER | 2020-01-01 | 通讯作者 |
| 22 | Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events | THORACIC CANCER | 2020-02-01 | 通讯作者 |
| 23 | Management of immune checkpoint inhibitor-related dermatologic adverse events | Thoracic Cancer | 2020-02-01 | 通讯作者 |
| 24 | Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity | THORACIC CANCER | 2020-02-01 | 通讯作者 |
| 25 | Abivertinib in patients with T790M-positive advanced NSCLC and its subsequent treatment with osimertinib | THORACIC CANCER | 2020-03-01 | 通讯作者 |
| 26 | Recommendation for the diagnosis and management of immune checkpoint inhibitor related infections | THORACIC CANCER | 2020-03-01 | 通讯作者 |
| 27 | Management of immune checkpoint inhibitor-related adverse events:A review of case reports | Thoracic Cancer | 2020-03-01 | 通讯作者 |
| 28 | Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy | THORACIC CANCER | 2020-03-01 | 通讯作者 |
| 29 | Histologic transformation of lung cancer during pembrolizumab therapy: A case report | THORACIC CANCER | 2020-03-01 | 通讯作者 |
| 30 | Marked elevation of creatine phosphokinase alone caused by sintilimab - beware of hypothyroid myopathy | EUROPEAN JOURNAL OF CANCER | 2020-03-01 | 通讯作者 |
| 31 | Tocilizumab for Fulminant Programmed Death 1 Inhibitor-Associated Myocarditis | JOURNAL OF THORACIC ONCOLOGY | 2020-03-01 | 通讯作者 |
| 32 | Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system | THORACIC CANCER | 2020-04-01 | 通讯作者 |
| 33 | Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction | THORACIC CANCER | 2020-04-01 | 通讯作者 |
| 34 | Opportunistic infections complicating immunotherapy for non-small cell lung cancer | THORACIC CANCER | 2020-04-01 | 通讯作者 |
| 35 | Opportunistic bowel infection after corticosteroid dosage tapering in a stage IV lung cancer patient with tislelizumab-related colitis | Thoracic Cancer | 2020-04-01 | 通讯作者 |
| 36 | Risk of GOVID-19 for patients with cancer | Lancet Oncology | 2020-04-01 | 通讯作者 |
| 37 | Single-center study to determine the safety and efficacy of CT-707 in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small-cell lung cancer | THORACIC CANCER | 2020-05-01 | 通讯作者 |
| 38 | Relationship between intestinal flora structure and metabolite analysis and immunotherapy efficacy in Chinese NSCLC patients | THORACIC CANCER | 2020-06-01 | 通讯作者 |
| 39 | Relationship between the efficacy of immunotherapy and characteristics of specific tumor mutation genes in non-small cell lung cancer patients | THORACIC CANCER | 2020-06-01 | 通讯作者 |
| 40 | Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study | Thoracic Cancer | 2020-07-01 | 通讯作者 |
| 41 | NLCIPS: Non-Small Cell Lung Cancer Immunotherapy Prognosis Score | CANCER MANAGEMENT AND RESEARCH | 2020-07-01 | 通讯作者 |
| 42 | Cancer Cachexia: Definition, Staging, and Emerging Treatments | CANCER MANAGEMENT AND RESEARCH | 2020-07-01 | 通讯作者 |
| 43 | Successful treatment of pyrotinib for bone marrow metastasis induced pancytopenia in a patient with non-small-cell lung cancer and ERBB2 mutation | Thoracic Cancer | 2020-07-01 | 通讯作者 |
| 44 | Recommendations and exploration of diagnosis and treatment of critical and refractory immune checkpoint inhibitor-associated adverse events | THORACIC CANCER | 2020-08-01 | 通讯作者 |
| 45 | Successful treatment of pulmonary inflammatory myofibroblastic tumor with platinum-pemetrexed: The first report of two cases | THORACIC CANCER | 2020-08-01 | 通讯作者 |
| 46 | Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients | THORACIC CANCER | 2020-09-01 | 通讯作者 |
| 47 | Use of glucocorticoids in the management of immunotherapy-related adverse effects | THORACIC CANCER | 2020-10-01 | 通讯作者 |
| 48 | Clinical characteristics and management of immune checkpoint inhibitor-related pneumonitis：A single-institution retrospective study | CANCER MEDICINE | 2020-11-01 | 通讯作者 |
| 49 | A phase III, randomized, double-blind, controlled trial of carboxyamidotriazole plus chemotherapy for the treatment of advanced non-small cell lung cancer | Therapeutic advances in medical oncology | 2020-11-01 | 通讯作者 |
| 50 | Non-small-cell lung cancer with ERBB2 mutation in non-typrosine kinase domain benefits from pyrotinib: A case report | Thoracic Cancer | 2020-12-30 | 通讯作者 |
| 51 | Genomic characteristics of driver genes in Chinese patients with non-small cell lung cancer | THORAC CANCER | 2021-02-21 | 通讯作者 |
| 52 | Clinical Recommendatins for perioperative immunotherapy-induced adverse events in patients with non-small cell lung cancer | Thoracic Cancer | 2021-05-01 | 通讯作者 |
| 53 | Application of Immune Checkpoint Inhibitors in Solid Organ Transplantation Recipients: A Systematic Review | Interdisciplinary Sciences-Computational Life Sciences | 2021-06-21 | 通讯作者 |
| 54 | Progress in Treatment of Non-small cell lung cancer harboring HER2 Aberrations | OncoTargets and Therapy | 2021-07-01 | 通讯作者 |
| 55 | Treatment of steroid-resistant checkpoint inhibitor pnuemonitis with prifenidone:A case report | Thoracic Cancer | 2021-08-01 | 通讯作者 |
| 56 | Second primary tumor after immune checkpoint inhibitor therapy: A case report | THORACIC CANCER | 2022-02-11 | 通讯作者 |
| 57 | Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China | Frontiers in Oncology | 2022-03-15 | 通讯作者 |
| 58 | Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer | Frontiers in Immunology | 2022-07-23 | 通讯作者 |
| 59 | Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer | Thoracic Cancer | 2023-02-26 | 通讯作者 |
| 60 | Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors | Frontiers in Immunology | 2023-03-23 | 通讯作者 |
| 61 | Camrelizumab plus platinumirinotecan followed by maintenance camrelizumab plus apatinib in untreated extensivestage small-cell lung cancer: a nonrandomized clinical trial | Frontiers in Immunology | 2023-04-11 | 通讯作者 |
- 科研获奖Research Awards
| # | 获奖证书编号 | 奖项名称 | 获奖级别 | 获奖类别 | 获奖等级 | 获奖日期 | 颁奖单位 | 本单位是否为第一完成单位 | 完成单位排名 | 本人排序 | 备注 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2019JB-1-022-R11 | 以针对性转化研究推进血管靶向治疗的完善、规范与更新 | 省部级 | 科技进步奖、哲学社科奖 | 一等奖 | 2020-01-22 | 天津市人民政府 | 否 | 5 | 11 | |
| 2 | 无 | 最具影响力药物临床研究领军人物奖 | 省部级 | 其他省部级奖励 | 特等奖 | 2019-09-16 | 中国医药创新促进会 | 是 | 1 | 1 | |
| 3 | 2015-J-235-1-01-R05 | 小分子靶向抗癌药盐酸埃克替尼开发研究、产业化和推广应用 | 国家级 | 国家最高科学技术奖、自然科学奖、技术发明奖、科技进步奖 | 一等奖 | 2015-12-16 | 国家科技部 | 否 | 4 | 5 | |
| 4 | 2020-HX-G-145 | 高影响力呼吸学术论文 | 省部级 | 其他省部级奖励 | 优秀奖 | 2020-10-23 | 中华医学会 | 是 | 1 | 1 | |
| 5 | 1201012-1 | 小分子靶向抗癌药盐酸埃克替尼开发研究、产业化和推广应用 | 省部级 | 科技进步奖、哲学社科奖 | 一等奖 | 2012-12-16 | 浙江省科技部 | 否 | 4 | 5 | |
| 6 | 2017-HX-J-001 | 杰出呼吸学术贡献奖 | 省部级 | 其他省部级奖励 | 特等奖 | 2017-09-27 | 中华医学会呼吸病学分会 | 是 | 1 | 1 | |
| 7 | 无 | 以精准转化研究推进血管靶向治疗的规范与创新 | 省部级 | 科技进步奖、哲学社科奖 | 二等奖 | 2020-07-25 | 中国抗癌协会 | 否 | 4 | 5 |
- 研究成果Research Findings
| # | 成果类型 | 项目/专利/新品种名称 |
|---|---|---|
| 1 | 出版高水平专著 | SITC的免疫疗法毒性管理指南 |
| 2 | 出版高水平专著 | 免疫检查点抑制剂相关不良反应200例病例精评 |
| 3 | 出版高水平专著 | 肺癌医患对话 |
| 4 | 出版高水平专著 | 呼吸内科主治医生760问 |
| 5 | 出版高水平专著 | 免疫治疗反应影像图谱 |
| 6 | 出版高水平专著 | 免疫检查点抑制剂相关不良反应200例病例精评 |
| 7 | 出版高水平专著 | SITC的免疫疗法毒性管理指南 |
| 8 | 出版高水平专著 | 免疫治疗反应影像图谱 |